Evidence map›Paper›PMID 31463103›Full record

ArticleJournal of thoracic disease2019

Visceral pleural invasion in T1 tumors (≤3 cm), particularly T1a, in the eighth tumor-node-metastasis classification system for non-small cell lung cancer: a population-based study.

Tao Zhang, Jia-Tao Zhang, Wen-Feng Li, Jun-Tao Lin, Si-Yang Liu, Hong-Hong Yan, Jin-Ji Yang, Xue-Ning Yang, Yi-Long Wu, Qiang Nie and 1 more

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Development and validation ofAnnals of nuclear medicine · 2023
    Article
  12. Article
  13. Multivariate analysis based on the maximum standard unit value ofDiagnostic and interventional radiology (Ankara, Turkey) · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tao ZhangShantou University Medical College, Shantou 515041, China.
Jia-Tao ZhangGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Wen-Feng LiGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Jun-Tao LinGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Si-Yang LiuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Hong-Hong YanGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Jin-Ji YangGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Xue-Ning YangGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Yi-Long WuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Qiang NieGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.
Wen-Zhao ZhongGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital Affiliated with the South China University of Technology and Guangdong Academy of Medical Sciences, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou 510080, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to validate the tumor (T) descriptors of visceral pleural invasion (VPI) for T1 tumors (<3 cm) in the 8th edition of the tumor-node-metastasis (TNM) classification system and the prognostic value of VPI for resected T1a tumors.

methodsThe external cohort consisted of 23,501 patients with resected pN0 non-small cell lung cancer (NSCLC) selected from the Surveillance, Epidemiology, and End Results (SEER) database (2010 to 2013). The classification of T1 tumors with VPI was investigated using survival curves. The internal cohort consisted of patients diagnosed with pN0 NSCLC between 2011 and 2013 at Guangdong Lung Cancer Institute. The prognostic value of VPI for T1a tumors (<1 cm) was further assessed in these two cohorts.

resultsThe overall survival (OS) and lung cancer-specific survival (LCSS) of the T1-VPI group and groups of each T stage (size only) were compared in the external (SEER) cohort. There were no significant survival differences between the T1-VPI and T2a groups (OS: P=0.706; LCSS: P=0.792) and T1-VPI and T2b groups, although the latter showed a trend toward lower P-values (OS: P=0.117; LCSS: P=0.094). In the internal cohort, a significant difference in OS was observed between patients with T1-VPI and those with T2b (P=0.049). Among patients with T1a tumors and VPI in the SEER database, the prognosis of the non-sub-lobectomy group was superior to that of the sub-lobectomy group, with intrathoracic recurrence as the predominant relapse pattern of T1 tumors with VPI (69.2%).

conclusionsT1 tumors (<3 cm) with VPI can be staged as T2a in the 8th TNM staging system and surgical resection of T1a tumors is a concern when VPI is present.

Indexed as

Non-small cell lung cancer (NSCLC)Surveillance, Epidemiology, and End Results database (SEER database)TNM classificationvisceral pleural invasion (VPI)

Identifiers

PMID31463103
PMCPMC6688036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.